• Mark Myslinski was named president/CEO of RedPath Integrated Pathology (Pittsburgh). Myslinski has been a Johnson & Johnson executive since 2002 where his responsibilities have included building a new, world-wide Evidence Based Medicine function for the Ortho-Clinical Diagnostics unit. RedPath Integrated Pathology is a genomics-based molecular diagnostics company that provides complex cancer diagnostic testing for pathologists, oncologists and clinicians.

• Trilochan Sahoo, MD, was named laboratory director of Signature Genomic Laboratories (Spokane, Washington). Sahoo previously spent six years as an assistant professor in the department of molecular and human genetics at Baylor College of Medicine. Signature Genomic Laboratories specializes in microarray-based cytogenetic diagnostic products.

• Kim Brodie, RN, was named the director of clinical education and support of Vidacare's (San Antonio) OnControl business unit. Brodie has more than twenty years of experience in hematology and oncology, most recently spending nearly a decade at the University of Texas M.D. Anderson Cancer Center in Houston. Vidacare makes intraosseous access technology for multiple diagnostic, monitoring and therapeutic applications.